1. Domagk G. Ein Beitrag zur Chemotherapie der bakteriellen Infektionen. Dtsch Med Wochenschr 1935; 61: 250–253.
2. Zinner SH, Mayer KH. Sulfonamides and Trimethoprim; Trimethoprim-Sulfamethoxazole. In: Bennett JE, Dolin R, Blaser MJ, eds. Mandell, Douglas, and Bennett’s Principles and Practice of
Infectious Diseases. 9th edition. Philadelphia, Elsevier; 2020.
3. Marko V. From Aspirin to Viagra: Stories of the Drugs that Changed the World. 1st edition. Cham, Schwitzerland, Springer Nature; 2020.
4. Bushby SRM, Hitchings GH. Trimethoprim, a sulphonamide potentiator. Br J Pharmacol 1968; 3372- 3390.
5. Masters PA, O’Bryan TA, Zurlo J, Miller DQ, Joshi N. Trimethoprim-sulfamethoxazole revisited. Arch Intern Med 2003; 163(4): 402-410.
6. Christensen SB. Drugs that changed society: History and current status of the early antibiotics: Salvarsan, sulfonamides, and β-lactams. Molecules 2021; 26(19): 6057.
7. Ovung A, Bhattacharyya J. Sulfonamide drugs: Structure, antibacterial property, toxicity, and biophysical interactions. Biophys Rev 2021; 13(2): 259-272.
8. Tačić A, Nikolić V, Nikolić L, Savić I. Antimicrobial sulfonamide drugs. Advanced technologies 2017; 6(1): 58-71.
9. El-Gaby M, A Ammar Y, IH El-Qaliei M, F Hussein M, A Faraghally F. Sulfonamides: synthesis and the recent applications in medicinal chemistry. Egypt J Chem 2020; 63(12): 5289-327.
10. Yousef F, Mansour O, Herbali J. Sulfonamides: historical discovery development (structure-activity relationship notes). IIIJ 2018; 1(1): 1-5.
11. Henry RJ. The mode of action of sulfonamides. Bacteriol Rev 1943; 7(4): 175-262.
12. Giles A, Foushee J, Lantz E, Gumina G. Sulfonamide allergies. Pharmacy 2019; 7(3): 132.
13. Chow TG, Khan DA. Sulfonamide hypersensitivity. Clinical Reviews in Allergy & Immunology. 2022 Jun 1:1-3.
14. Lei H, Liu X, Zeng J, et al. Analysis of the clinical characteristics of hyponatremia induced by trimethoprim/sulfamethoxazole. Pharmacology 2022; 107(7-8): 351-8.
15. Libecco JA, Powell KR. Trimethoprim/sulfamethoxazole: clinical update. Pediatr Rev 2004; 25(11): 375–80.
16. Bakdach D, Elajez R. Trimethoprim–Sulfamethoxazole: new lessons on an old antimicrobial; a retrospective analysis. J Pharm Health Serv Res 2020; 11(3): 269–274.
17. Kato H, Hagihara M, Asai N,et al. Efficacy of trimethoprim–sulfamethoxazole in combination with an echinocandin as a first-line treatment option for Pneumocystis pneumonia: a systematic
review and meta-analysis. Antibiotics 2022; 11(6): 719.
18. Sierra Y, Tubau F, González-Díaz A, et al. Assessment of trimethoprim-sulfamethoxazole susceptibility testing methods for fastidious Haemophilus spp. Clin Microbiol Infect 2020; 26(7):
944-e1.
19. DeMarsh M, Bookstaver PB, Gordon C, et al. Prediction of trimethoprim/sulfamethoxazole resistance in community-onset urinary tract infections. J Glob Antimicrob Resist 2020; 21: 218-
222.
20. Ho JM, Juurlink DN. Considerations when prescribing trimethoprim–sulfamethoxazole. Cmaj. 2011; 183(16): 1851-1858.
21. Shtroblya АL, Drogovoz SМ, Shchokina KG, et al. Features of side effects of sulfamethoxazole/Trimethoprim combined pharmacotherapy. Archives 2021; 3: 1855-1862.
22. Ju M, Zheng M, Yuan J, Lin D, Qian Y. Prevalence and risk factors of trimethoprim/sulfamethoxazole-related acute kidney injury in pediatric patients: an observational study from a public
database. Transl Pediatr 2022; 11(8): 1285.
23. Shtroblya АL, Drogovoz SМ, Shchokina KG, et al. Potential risks of sulfametoxazole/Trimetoprim. Archives 2021; 3: 2065-2074.
24. Naveed S, Chidharla A, Aedma KK. Trimethoprim-sulfamethoxazole-induced exacerbation of anxiety and depression. Prim Care Companion CNS Disord 2018; 20(4): 26963.
25. Wang C, Fang W, Li Z, Sun L. Clinical features, risk factors, diagnosis, and treatment of trimethoprim-sulfamethoxazole-induced hypoglycemia. Front Endocrinol 2023; 14: 1059522.
26. Yang C, Xiang Y, Qiu S. Resistance in Enteric Shigella and nontyphoidal Salmonella: emerging concepts. Curr Opin Infect Dis 2023; 36(5): 360-365.
27. Talan DA, Mower WR, Krishnadasan A, et al. Trimethoprim-Sulfamethoxazole versus Placebo for Uncomplicated Skin Abscess. N Engl J Med 2016; 374(9): 823-32.
28. Hassan WA, Abdel-Gawad M, Abdelmohsen AS. Doxycycline Plus Trimethoprim-Sulfamethoxazole versus Doxycycline plus Rifampicin in Treatment of Brucellosis: A Randomized Control-
led Trial. Al-Azhar Assiut Med j 2022; 20(4): 333-337.
29. Braddick M, Woods ML, Prabhaharan S. Acute Q fever in third trimester pregnancy. BMJ Case Rep 2021; 14(8): e242558.
30. Song JE, Kim S, Kwak YG, et al. A 20-year trend of prevalence and susceptibility to trimethoprim/sulfamethoxazole of Stenotrophomonas maltophilia in a single secondary care hospital in
Korea. Medicine 2023;102(4): e32704.
31. Prosty C, Hanula R, Levin Y, Bogoch II, McDonald EG, Lee TC. Revisiting the evidence base for modern-day practice of the treatment of toxoplasmic encephalitis: a systematic review and
meta-analysis. Clin Infect Dis 2023; 76(3): e1302-19.
32. Haseeb A, Abourehab MA, Almalki WA, et al. Trimethoprim-sulfamethoxazole (bactrim) dose optimization in Pneumocystis jirovecii pneumonia (PCP) management: A systematic review.
Int J Environ Res Public Health 2022; 19(5): 2833.
33. Hammarström H, Krifors A, Athlin S, et al. Treatment with reduced-dose trimethoprim-sulfamethoxazole is effective in mild to moderate Pneumocystis jirovecii pneumonia in patients with
hematologic malignancies. Clin Infect Dis 2023; 76(3): e1252-60.
34. EACS, 2023 [İnternet, erişim 28 Nisan 2024]. https://www.eacsociety.org/media/guidelines-12.0.pdf
35. Castaldo N, Vena A, Limongelli A, Giacobbe DR, Bassetti M. Emerging treatment options for skin and soft tissue infections tailoring drug selection to individual patients. Curr Opin Infect
Dis 2024; 37(2): 80-6